>95% of eligible adults aren't getting the nationally recommended screening1

Lung cancer is the leading cause of cancer death in the United States.2 15.1 million Americans are at an elevated risk for the disease* but fewer than 5 percent get recommended screening with a low-dose CT scan.1,3 While lung cancer is most treatable when caught in its early stages, most people do not initially show any signs or symptoms.

The FirstLook blood test has a negative
predictive value of 99.8%.4

  • FirstLook is a simple and efficient laboratory developed blood test that can be added to routine bloodwork during an individual's health check.

  • FirstLook's breakthrough technology analyzes DNA fragment patterns (fragmentomics) in the blood to help detect lung cancer with high sensitivity. Our test provides clear results to help patients and healthcare providers determine the next best step in the screening process.

  • FirstLook's whole-genome sequencing and machine learning approach makes screening more accessible for everyone who needs it.

Learn More About Firstlook

If you are a health system interested in learning more about how FirstLook can facilitate the lung cancer screening process at your institution, please contact DELFI.

*Individuals who are over 50 with a specific history of smoking may be eligible for lung cancer screening.

We look forward to meeting you!

Learn more about FirstLook and DELFI's fragmentomics approach at upcoming industry meetings:

  • Meet DELFI representatives at the Go2 for Lung Cancer 2024 Centers of Excellence (COE) Summit, September 30 - October 2, in Chicago to learn more about the FirstLook Lung test.

    Learn more

  • Meet DELFI representatives at HLTH 2024, October 20-23, in Las Vegas, to learn more about the FirstLook Lung test and its use for Health Systems and other Partners.

    Learn more

Beyond FirstLook

DELFI is committed to bringing additional products to market that address major unmet medical needs with strong demand for new solutions. We are taking a scientifically rigorous and sustainable approach to ongoing innovation with our DELFI platform.

DELFI has published promising proof-of-concept data in other cancer types. As our platform is designed to be flexibly deployed, we are also building a body of evidence to show how the DELFI platform can be used for monitoring and minimal residual disease (MRD) applications.

References: 1. State of Lung Cancer | Key Findings | American Lung Association. Accessed December 21, 2023. 2. NIH National Cancer Institute. Cancer Stat Facts: Common Cancer Sites. 3. Meza R et al. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography Modeling Study for the US Preventive Services Task Force. JAMA. 2021;325(10):988-997. 4. Mazzone, P.J., Bach, P.B., Carey, J., et al. Cancer Discovery. 10.1158 – 2159-8290. CD-24-0519. (2024).

The FirstLook Lung test is a laboratory-developed test. It was developed and its performance characteristics determined by DELFI Diagnostics. It has not been cleared or approved by the FDA. The laboratory is regulated under the Clinical Laboratory Improvement Act (CLIA) as qualified to perform high complexity clinical tests. This test is used for clinical purposes. It should not be regarded as investigational or for research.

FirstLook is a trademark of DELFI Diagnostics, Inc. used worldwide.